# A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

> **NCT02215252** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 141 (actual)

## Conditions studied

- Diabetic Neuropathy, Painful

## Interventions

- **DRUG:** PF-05089771 150 mg
- **DRUG:** Matched placebo for PF-05089771 150 mg and pregabalin 300 mg
- **DRUG:** Pregabalin 300 mg
- **DRUG:** PF-05089771 150 mg + Pregabalin 300 mg

## Key facts

- **NCT ID:** NCT02215252
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-10
- **Primary completion:** 2015-07-15
- **Final completion:** 2015-09-28
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2017-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02215252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02215252, "A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02215252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*